Eyetech Pharmaceuticals Inc.

Eyetech Pharmaceuticals believes that blocking angiogenesis is the best route to improved therapy for age-related macular degeneration and diabetic macular edema, degenerative conditions that frequently and quickly lead to serious vision loss and blindness. The company in-licensed a compound from Gilead Sciences, about to enter pivotal clinical trials, that it thinks does just that.

For the most part, start-ups begin life with a license to raw technology, at best a couple of compounds in very early development, and little commercial infrastructure. That was not the case with EyeTech Pharmaceuticals Inc. , however, which got its start in large part because it had a development infrastructure, which enabled it to in-license a product from a major biotech company.

Company co-founder David Guyer, MD, a professor of ophthalmology at New York University Medical Center , believed that blocking...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip